Peter Browett

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 336 citations · Full text

Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency

Manfred Fliegauf, Vanessa L. Bryant, Natalie Frede et al. · The American Journal of Human Genetics · 2015 · 239 citations · Full text

Primary Immunodeficiency, Immunodeficiencies, Immunology +10

FAMILIAL GIANT HYPERPLASTIC POLYPOSIS PREDISPOSING TO COLORECTAL CANCER: A NEW HEREDITARY BOWEL CANCER SYNDROME

P. JEEVARATNAM, D. S. COTTIER, Peter Browett et al. · The Journal of Pathology · 1996 · 168 citations

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 165 citations

Hematological Malignancy, Oncology, Malignant Blood Disorder +8

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Susan Branford, Zbigniew Rudzki, Andrew Harper et al. · Leukemia · 2003 · 157 citations

Chronic Phase, Hematological Malignancy, Chronic Myeloid Leukemia +10